News

Filter

Current filters:

Targretin

1 to 9 of 57 results

Valeant Pharma buys US rights to Eisai's Targretin for $65 million upfront

21-02-2013

Canada's Valeant Pharmaceuticals International (TSX: VRX) says that it has acquired US rights for Targretin…

EisaiLicensingNorth AmericaOncologyPharmaceuticalTargretinValeant Pharmaceuticals

Eisai licenses bexarotene to Minophagen forJapan; Roche opts for Invida for Korean marketing

04-04-2011

Japanese drug major Eisai (TYO: 4532) has granted a license Minophagen Pharmaceutical, based in Tokyo,…

Asia-PacificbexaroteneEisaiInvidaLicensingMinophagenOncologyPharmaceuticalRocheTargretin

Stock Commentary - New York week to Sept 15, 2008

22-09-2008

NEW YORK: equities saw another roller-coaster week in the reporting period to September 15. Having breathed…

AlpharmaAmgenbexaroteneTargretin

Ligand to settle dispute with Salk Institute

15-09-2008

USA-based Ligand Pharmaceuticals has entered a settlement agreement in its dispute with the Salk Institute…

bexaroteneEisaiTargretinWyeth

Stock Commentary - New York week to April 9

16-04-2007

NEW YORK: equities moved higher during the holiday-shortened reporting period to April 9, with the Dow…

bexarotenecetuximabErbituxNystatinOralTargretinWyeth

Japan's Eisai spreads its wings with $325 million acquisition of USA's Morphotek

02-04-2007

In what it describes as a "dramatic leap towards biologic therapeutics," Japan's fourth-largest pharmaceutical…

AlitretinoinAriceptbexaroteneDenileukin DiftitoxdonepezilEisaiOntakPanretinTargretin

Ligand finalizes sale of oncology line to Eisai

06-11-2006

San Diego, USA-based Ligand Pharmaceuticals says it has completed the sale of its oncology product line…

AlitretinoinbexaroteneDenileukin DiftitoxEisaiOntakPanretinTargretin

1 to 9 of 57 results

Back to top